All Updates

All Updates

icon
Filter
FDA approval
UniQure receives RMAT designation for AMT-130 gene therapy for Huntington’s disease
Cell & Gene Therapy
Jul 9, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 9, 2024

UniQure receives RMAT designation for AMT-130 gene therapy for Huntington’s disease

FDA approval

  • UniQure has announced that the FDA has granted it the Regenerative Medicine Advanced Therapy (RMAT) designation for its developmental gene therapy for Huntington's disease.

  • The gene therapy, AMT-130, was tested in a Phase I/II trial with 21 patients for 24 months. The disease progression was measured using the composite Unified Huntington’s Disease Rating Scale. The company claims that in higher doses, AMT-130 slowed disease progression by 80%. The RMAT designation has been granted for the therapy following the reported positive results from the trials. 

  • Based in the Netherlands, uniQure is a gene therapy company specializing in developing and commercializing adeno-associated virus (AAV) based therapies. The company aims to provide novel treatments for patients with severe genetic diseases. Its leading product, AMT-060, is a gene therapy for treating moderately severe hemophilia B. The company's pipeline includes AMT-130 for Huntington's disease and AMT-150 for Spinocerebellar Ataxia type 3. UniQure leverages its proprietary gene technology platform to develop, manufacture, and test these therapies, targeting liver-directed and central nervous system (CNS) disorders​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.